"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

Stock Information for Longeveron Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Longeveron Inc.

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
The $13 Million Company Teaching the Immune System to Hunt Cancer
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
GT Biopharma Reports First Quarter 2026 Financial Results
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.